Article Details
Retrieved on: 2024-05-16 14:40:06
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Roche's successful Phase Ib trial of CT-388, a GLP-1 and GIP receptor agonist for obesity and type 2 diabetes, compared to Eli Lilly's Mounjaro. It emphasizes biotechnology's role in developing peptide therapeutics, featuring key players such as Novo Nordisk and Eli Lilly.
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here